Pliant Therapeutics to Participate in BTIG Biotechnology Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology company, announced that Dr. Bernard Coulie will participate in a panel on drug development in pulmonary medicine at the BTIG Biotechnology Conference 2022. The event is scheduled for August 9, 2022, at 1:00 p.m. ET. Pliant is focused on developing therapies for fibrosis, with its lead candidate, PLN-74809, in Phase 2a trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The panel discussion will be available via the BTIG portal for registered participants.

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BTIG Biotechnology Conference 2022.

Panel:		Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need
Date:		Tuesday, August 9, 2022
Time:		1:00 p.m. ET | 10:00 a.m. PT

The live and replay sessions of the panel discussion will be available to conference registrants via the BTIG Biotechnology Conference 2022 portal.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF), and primary sclerosing cholangitis (PSC). PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in PSC. Pliant is currently conducting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

What is the date and time of the BTIG conference panel featuring Pliant Therapeutics?

The BTIG conference panel featuring Pliant Therapeutics is on August 9, 2022, at 1:00 p.m. ET.

Who from Pliant Therapeutics will participate in the BTIG conference?

Dr. Bernard Coulie, President and CEO of Pliant Therapeutics, will participate in the BTIG conference.

What is the main topic of the Pliant Therapeutics panel discussion?

The panel discussion will focus on drug development in pulmonary medicine, including emerging trends and unmet needs.

What is PLRX's lead product candidate?

Pliant Therapeutics' lead product candidate is PLN-74809, aimed at treating idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

What designations has PLN-74809 received?

PLN-74809 has received Fast Track and Orphan Drug Designation from the FDA for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.